Search
Elranatamab
go.drugbank.com/drugs/DB15395ApprovedInvestigational[L47820] Elranatamab was also approved by the European Commission on December 8, 2023.[L50437] … [L47815] On August 14, 2023, the FDA granted accelerated approval to elranatamab for the treatment of multiple myeloma.
Allogeneic cultured keratinocytes and dermal fibroblasts in murine collagen
go.drugbank.com/drugs/DB16709ApprovedThe product does not remain permanently engrafted, instead being replaced by the patient's own cells over time, which can reduce or even eliminate the need for autografting. … [L35505] It was developed as an alternative to autografting - the process by which a patient's own skin is harvested and grafted onto the burn site - which has the disadvantage of creating a new wound
Tamoxifen
go.drugbank.com/drugs/DB00675ApprovedInvestigational[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. … Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.
Synonyms: (Z)-2-(4-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylethanamine, (Z)-2-(para-(1,2-Diphenyl-1-butenyl)phenoxy)-N,N-dimethylamineTeriflunomide
go.drugbank.com/drugs/DB08880ApprovedInvestigationalTeriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis.
Categories: Analgesics, Non-NarcoticNicoboxil
go.drugbank.com/drugs/DB12911ApprovedWithdrawnbe used as an alternative musculoskeletal pain therapy option with less systemic side effects when compared to the oral non-steroidal anti-inflammatory drugs and opioids that may be more typically prescribed … nicoboxil/nonivamide topical analgesic medication being used since the 1950s, recent studies demonstrate continued interest in the medication(s) given its demonstrated efficacy, safety, and capability to
Sodium cellulose phosphate
go.drugbank.com/drugs/DB06776Approved[A31694] This compound is an ion-exchange resin that can not be absorbed by the body. However, it can be used to restore normal intestinal calcium absorption. … Sodium cellulose phosphate is used to treat hypercalcemia and hypercalciuria. It has been used to prevent kidney stones.
Givinostat
go.drugbank.com/drugs/DB12645ApprovedInvestigationalIn the context of muscular dystrophy, inhibitors of HDAC appear to exert their therapeutic effects by targeting pathogenic processes that cause inflammation and muscle loss. … [L50311,L50316] It is the first non-steroidal drug approved to treat patients with all genetic variants of DMD.[L50316]
Lyme disease vaccine (recombinant OspA)
go.drugbank.com/drugs/DB00045ApprovedWithdrawnVaccine against Lyme disease that contains lipoprotein OspA, an outer surface protein of Borrelia burgdorferi sensu stricto ZS7, as expressed by Escherichia coli. … Lipoprotein OspA is a single polypeptide chain of 257 amino acids with lipids covalently bonded to the N terminus. It is conjugated with alum (aluminum hydroxide) as an adjuvant.
Oprelvekin
go.drugbank.com/drugs/DB00038ApprovedInvestigationalWithdrawnHowever, it displays comparable biological activity compared to the natural IL-11 _in vitro_ and _in vivo_. Oprelvekin works by stimulating megakaryocytopoiesis and thrombopoiesis. … In animal studies, oprelvekin was also shown to regulate intestinal epithelium growth by enhancing healing of gastrointestinal lesions, inhibit adiopegenesis and macrophageal released pro-inflammatory